The Role of NLRP3 Inflammasome Activation Pathway of Hepatic Macrophages in Liver Ischemia-Reperfusion Injury.

The Role of NLRP3 Inflammasome Activation Pathway of Hepatic Macrophages in Liver Ischemia-Reperfusion Injury.
复制标题

肝巨噬细胞炎性小体激活通路NLRP3在肝脏缺血再灌注损伤中的作用

DOI:
10.3389/fimmu.2022.905423
复制
发表时间:
2022
影响因子:
7.3
通讯作者:
Chen, Diyu
Chen, Diyu
中科院分区:
医学2区
文献类型:
--
作者:
Wu, Tong;Zhang, Cheng;Shao, Tianfeng;Chen, Jianzhong;Chen, Diyu

文献摘要

参考文献

相似文献

缺血再灌注损伤(IRI)被认为是肝移植的固有组成部分,可导致早期器官功能障碍和衰竭。越来越多的证据表明宿主先天免疫系统特别是肝巨噬细胞的激活在LIRI的进展中发挥着关键作用。炎症小体是一种细胞内多分子复合物,积极参与先天免疫反应和促炎信号通路。其中,NLRP3 炎症小体的特征最为明确,它对应于调节 caspase-1 的激活和促炎细胞因子的分泌,以响应各种病原体来源的以及与危险相关的信号。此外,NLRP3在肝巨噬细胞中高表达,NLRP3炎性小体的组装可能导致LIRI,这使其成为一个有前途的治疗靶点。然而,关于NLRP3炎症小体参与肝巨噬细胞相关LIRI的详细机制却很少总结。在这里,我们回顾了肝巨噬细胞的 NLRP3 炎症小体通路在 LIRI 中的潜在作用,并重点介绍了目前可用的治疗方案。
Ischemia-reperfusion injury (IRI) is considered an inherent component involved in liver transplantation, which induce early organ dysfunction and failure. And the accumulating evidences indicate that the activation of host innate immune system, especially hepatic macrophages, play a pivotal role in the progression of LIRI. Inflammasomes is a kind of intracellular multimolecular complexes that actively participate in the innate immune responses and proinflammatory signaling pathways. Among them, NLRP3 inflammasome is the best characterized and correspond to regulate caspase-1 activation and the secretion of proinflammatory cytokines in response to various pathogen-derived as well as danger-associated signals. Additionally, NLRP3 is highly expressed in hepatic macrophages, and the assembly of NLRP3 inflammasome could lead to LIRI, which makes it a promising therapeutic target. However, detailed mechanisms about NLRP3 inflammasome involving in the hepatic macrophages-related LIRI is rarely summarized. Here, we review the potential role of the NLRP3 inflammasome pathway of hepatic macrophages in LIRI, with highlights on currently available therapeutic options.
DOI: 10.1002/hep.24341
发表时间: 2011-07
期刊: HEPATOLOGY
影响因子: 13.5
作者:
Csak, Timea;Ganz, Michal;Pespisa, Justin;Kodys, Karen;Dolganiuc, Angela;Szabo, Gyongyi
通讯作者: Szabo, Gyongyi
DOI: 10.1146/annurev-immunol-032414-112240
发表时间: 2015
影响因子: 29.7
作者:
Brubaker SW;Bonham KS;Zanoni I;Kagan JC
通讯作者: Kagan JC
DOI: 10.5500/wjt.v11.i6.187
发表时间: 2021-06-18
期刊: World journal of transplantation
影响因子: --
作者:
Kumar R;Anand U;Priyadarshi RN
通讯作者: Priyadarshi RN
DOI: 10.1038/s41388-018-0390-1
发表时间: 2018-12-06
期刊: ONCOGENE
影响因子: 8
作者:
Ferro, R.;Adamska, A.;Falasca, M.
通讯作者: Falasca, M.
阻断先天免疫细胞而非肝细胞中的 GSDMD 处理可保护肝脏缺血再灌注损伤
DOI: 10.1038/s41419-020-2437-9
发表时间: 2020-04-17
影响因子: 9
作者:
Li, Jichang;Zhao, Jie;Kong, Xiaoni
通讯作者: Kong, Xiaoni